Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Mutant Natural Killer Cell Dysfunction Enables the Immune Escape of Premalignant MDS Cell Clones

Blood (2023) 142 (Supplement 1): 514.

https://doi.org/10.1182/blood-2023-184349

Published: 2023

Journal Articles

Myelodysplastic Syndrome Hematopoietic Stem Cells Can Undergo Differentiation Trajectory Rewiring to Escape Venetoclax Vulnerability

Juan Jose Rodriguez Sevilla, Irene Ganan-Gomez, Feiyang Ma, Kelly S. Chien, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Sanam Loghavi, Vera Adema, Natthakan Thongon, Alexandre Bazinet, Guillermo Garcia-Manero, Simona Colla

Blood (2023) 142 (Supplement 1): 584.

https://doi.org/10.1182/blood-2023-180447

Published: 2023

Journal Articles

A Phase 2 Study of Canakinumab in Patients with Lower-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Juan Jose Rodriguez Sevilla, Vera Adema, Kelly S. Chien, Irene Ganan-Gomez, Guillermo Montalban-Bravo, Samuel Urrutia, Joby Joseph, Hui Yang, Gautam Borthakur, Nicholas J. Short, Ghayas C. Issa, Tapan M. Kadia, Koichi Takahashi, Danielle E. Hammond, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 1866.

https://doi.org/10.1182/blood-2023-185259

Published: 2023

Journal Articles

Impact of Spliceosome Mutations on the Prognosis of Myelodysplastic Syndrome (MDS)

Samuel Urrutia, Koji Sasaki, Rashmi Kanagal-Shamanna, Alex Bataller, Guillermo Montalban-Bravo, Irene Ganan-Gomez, Yue Wei, Hui Yang, Kelly S. Chien, Danielle Hammond, Carlos E. Bueso-Ramos, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2022) 140 (Supplement 1): 6952–6954.

https://doi.org/10.1182/blood-2022-165488

Published: 2022

Journal Articles

Myelodysplastic Syndromes without Detectable Mutations: Analysis of Clinical Presentation and Outcome

Alex Bataller, Rashmi Kanagal-Shamanna, Kelly S. Chien, Guillermo Montalban-Bravo, Tapan M. Kadia, Farhad Ravandi, Courtney D. DiNardo, Naval Daver, Nicholas Short, Gautam Borthakur, Elias Jabbour, Danielle Hammond, Lucia Masarova, Irene Ganan-Gomez, Vera Adema, Hagop Kantarjian, Guillermo Garcia-Manero, Koji Sasaki

Blood (2022) 140 (Supplement 1): 9793–9795.

https://doi.org/10.1182/blood-2022-164962

Published: 2022

Journal Articles

Clinical and Biological Effects of Canakinumab in Lower-Risk Myelodysplastic Syndromes (MDS): Results from a Phase 2 Clinical Trial

Guillermo Garcia-Manero, Vera Adema, Samuel Urrutia, Feiyang Ma, Hui Yang, Irene Ganan-Gomez, Gautam Borthakur, Koichi Takahashi, Nicholas Short, Ghayas C. Issa, Kelly S. Chien, Guillermo Montalban-Bravo, Joby Joseph, Simona Colla

Blood (2022) 140 (Supplement 1): 2078–2080.

https://doi.org/10.1182/blood-2022-167703

Published: 2022

Journal Articles

Cancer Chemotherapy Accelerates the Loss of Clonal Diversity in Hematopoietic Stem Cells and Promotes the Convergent Evolution of Therapy-Related Clonal Hematopoiesis

Blood (2022) 140 (Supplement 1): 2232–2233.

https://doi.org/10.1182/blood-2022-160294

Published: 2022

Journal Articles

Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure

Blood (2022) 140 (Supplement 1): 9773–9775.

https://doi.org/10.1182/blood-2022-169213

Published: 2022

Journal Articles

Transcriptomic Signitures of Azacitidine (AZA) and Decitabine (DAC) Resistance in MDS and CMML

Faezeh Darbaniyan, Caleb Class, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Marcos Estecio, Yue Lu, Kelly A. Soltysiak, Kelly S. Chien, Hui Yang, Koji Sasaki, Irene Ganan-Gomez, Simona Colla, Kim-Anh Do, Guillermo Garcia-Manero, Yue Wei

Blood (2021) 138 (Supplement 1): 4652.

https://doi.org/10.1182/blood-2021-153698

Published: 2021

Journal Articles

Single-Cell RNA Sequencing Analysis Reveals Mechanisms of Initiation and Progression in Chronic Myelomonocytic Leukemia

Guillermo Montalban-Bravo, Feiyang Ma, Irene Ganan-Gomez, Rashmi Kanagal-Shamanna, Vera Adema, Yue Wei, Kelly S. Chien, Natthakan Thongon, Hui Yang, Carlos E. Bueso-Ramos, Hagop Kantarjian, Guillermo Garcia-Manero, Simona Colla

Blood (2021) 138 (Supplement 1): 2588.

https://doi.org/10.1182/blood-2021-151340

Published: 2021

Journal Articles

The Transcriptional and Epigenetic Reprogramming of Aged Hematopoietic Stem Cells Drives Myeloid Rewiring in Clonal Hematopoiesis-Associated Cytopenias

Irene Ganan-Gomez, Kelly S. Chien, Feiyang Ma, Hui Yang, Lin Tan, Philip Lorenzi, Guillermo Garcia-Manero, Simona Colla

Blood (2021) 138 (Supplement 1): 3273.

https://doi.org/10.1182/blood-2021-150663

Published: 2021

Journal Articles

Inhibition of MDM2 Improves the Therapeutic Effect of Hypomethylating Agents in Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Yue Wei, Hong Zheng, Pamela Lockyer, Naran Bao, Faezeh Darbaniyan, Ziyi Li, Rashmi Kanagal-Shamanna, Kelly A. Soltysiak, Hui Yang, Irene Ganan-Gomez, Kim-Anh Do, Simona Colla, Kelly S. Chien, Guillermo Montalban-Bravo, Naval Daver, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 3664.

https://doi.org/10.1182/blood-2021-150811

Published: 2021

Journal Articles

Targeting DNA2 Overcomes Myeloma Cells' Metabolic Reprogramming in Response to DNA Damage

Natthakan Thongon, Andrea Santoni, Jintan Liu, Natalia Baran, Feiyang Ma, Christopher Jackson, Pamela Lockyer, Irene Ganan-Gomez, Vera Adema, Ashley Rose, Matteo Marchesini, Yun Qing, Min Jin Ha, Caleb Class, Matteo Pellegrini, Lin Tan, Philip Lorenzi, Marina Konopleva, Simona Colla

Blood (2021) 138 (Supplement 1): 1573.

https://doi.org/10.1182/blood-2021-148992

Published: 2021

Journal Articles

Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-141411

Published: 2020

Journal Articles

Genomic and Transcriptomic Differences of Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)

Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Faezeh Darbaniyan, PhD, Irene Ganan-Gomez, PhD, Koji Sasaki, MD, Kiran Naqvi, MD MPH, Yue Wei, PhD, Hui Yang, MD PhD, Kelly A. Soltysiak, PhD, Kelly S. Chien, MD, Carlos E. Bueso-Ramos, MD PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139983

Published: 2020

Journal Articles

Transcriptomic Features and Deregulation of Genes Involved in Monopoiesis Influence Outcomes of Patients with Chronic Myelomonocytic Leukemia

Guillermo Montalban Bravo, MD, Faezeh Darbaniyan, PhD, Rashmi Kanagal-Shamanna, MD, Irene Ganan-Gomez, PhD, Koji Sasaki, MD, Kiran Naqvi, MD MPH, Yue Wei, PhD, Hui Yang, MD PhD, Kelly A. Soltysiak, PhD, Kelly S. Chien, MD, Carlos E. Bueso-Ramos, MD PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-137702

Published: 2020

Journal Articles

SF3B1 -Mutant Myelodysplastic Syndrome with Ringed Sideroblasts (MDS-RS) at the Single-Cell Level

Rashmi Kanagal-Shamanna, MD, Vera Adema, PhD, Feiyang Ma, Bs, Andrea Santoni, PhD, Hui Yang, MD PhD, Irene Ganan-Gomez, PhD, Natthakan Thongon, PhD, Guillermo Montalban-Bravo, MD, Matteo Pellegrini, PhD, Carlos E. Bueso-Ramos, MD PhD, Guillermo Garcia-Manero, MD, Simona Colla, PhD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-141928

Published: 2020

Journal Articles

Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Rashmi Kanagal-Shamanna, MD, Guillermo Montalban-Bravo, MD, Caleb Class, PhD, Koji Sasaki, MD, Christopher B. Benton, MD, Kelly Soltysiak, PhD, Elias Jabbour, MD, Tapan M. Kadia, MD, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Mark Routbort, MD PhD, Irene Ganan-Gomez, PhD, Yue Wei, PhD, Gautam M. Borthakur, MD, Farhad Ravandi, MD, Kim-Anh Do, PhD, L. Jeffrey Medeiros, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 1719.

https://doi.org/10.1182/blood-2019-130545

Published: 2019

Journal Articles

Transcriptomic Analysis Implicates Necroptosis in Disease Progression and Prognosis in Myelodysplastic Syndromes

Guillermo Montalban-Bravo, MD, Caleb Class, PhD, Irene Ganan-Gomez, PhD, Rashmi Kanagal-Shamanna, MD, Koji Sasaki, MD, Guillaume Richard-Carpentier, MD, Kiran Naqvi, MDMPH, Yue Wei, PhD, Hui Yang, PhDMD, Kelly Soltysiak, PhD, Kelly S. Chien, MD, Carlos E. Bueso-Ramos, MD PhD, Kim-Anh Do, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 3006.

https://doi.org/10.1182/blood-2019-124957

Published: 2019

Journal Articles

KDM6B Overexpression and TET2 Deficiency Cooperatively Drive Development of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-like Phenotype in Mice

Yue Wei, PhD, Hong Zheng, Naran Bao, Rashmi Kanagal-Shamanna, MD, Caleb Class, PhD, Hui Yang, PhDMD, Guillermo Montalban Bravo, MD, Irene Ganan-Gomez, PhD, Kelly Soltysiak, PhD, Kim-Ann Do, Simona Colla, PhD, Carlos E. Bueso-Ramos, MD PhD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 562.

https://doi.org/10.1182/blood-2019-122574

Published: 2019

NARROW

Mutant Natural Killer Cell Dysfunction Enables the Immune Escape of Premalignant MDS Cell Clones

Myelodysplastic Syndrome Hematopoietic Stem Cells Can Undergo Differentiation Trajectory Rewiring to Escape Venetoclax Vulnerability

A Phase 2 Study of Canakinumab in Patients with Lower-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Impact of Spliceosome Mutations on the Prognosis of Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes without Detectable Mutations: Analysis of Clinical Presentation and Outcome

Clinical and Biological Effects of Canakinumab in Lower-Risk Myelodysplastic Syndromes (MDS): Results from a Phase 2 Clinical Trial

Cancer Chemotherapy Accelerates the Loss of Clonal Diversity in Hematopoietic Stem Cells and Promotes the Convergent Evolution of Therapy-Related Clonal Hematopoiesis

Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure

Transcriptomic Signitures of Azacitidine (AZA) and Decitabine (DAC) Resistance in MDS and CMML

Single-Cell RNA Sequencing Analysis Reveals Mechanisms of Initiation and Progression in Chronic Myelomonocytic Leukemia

The Transcriptional and Epigenetic Reprogramming of Aged Hematopoietic Stem Cells Drives Myeloid Rewiring in Clonal Hematopoiesis-Associated Cytopenias

Inhibition of MDM2 Improves the Therapeutic Effect of Hypomethylating Agents in Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Targeting DNA2 Overcomes Myeloma Cells' Metabolic Reprogramming in Response to DNA Damage

Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis

Genomic and Transcriptomic Differences of Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)

Transcriptomic Features and Deregulation of Genes Involved in Monopoiesis Influence Outcomes of Patients with Chronic Myelomonocytic Leukemia

SF3B1 -Mutant Myelodysplastic Syndrome with Ringed Sideroblasts (MDS-RS) at the Single-Cell Level

Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Transcriptomic Analysis Implicates Necroptosis in Disease Progression and Prognosis in Myelodysplastic Syndromes

KDM6B Overexpression and TET2 Deficiency Cooperatively Drive Development of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-like Phenotype in Mice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only